B-cell Malignancy

Oncology·MeSH: Lymphoma, Non-Hodgkin

10 drugs in development·2 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(9)

Drug	Company
bgb-16673	BeOne Medicines Ltd. (ONC)
BGB-16673	BeOne Medicines Ltd. (ONC)
mosunetuzumab	BeOne Medicines Ltd. (ONC)
Mosunetuzumab	BeOne Medicines Ltd. (ONC)
obinutuzumab	BeOne Medicines Ltd. (ONC)
obinutuzumab	BeOne Medicines Ltd. (ONC)
Obinutuzumab	BeOne Medicines Ltd. (ONC)
sonrotoclax	BeOne Medicines Ltd. (ONC)
Sonrotoclax	BeOne Medicines Ltd. (ONC)

Phase 1(1)

Drug	Company
CTX110	CRISPR Therapeutics AG (CRSP)

Compare drugs

bgb-16673 vs mosunetuzumab bgb-16673 vs obinutuzumab bgb-16673 vs sonrotoclax

Frequently asked questions

How many drugs are in development for B-cell Malignancy?

BioSniper tracks 10 drugs in development for B-cell Malignancy across 2 companies.

How many clinical trials target B-cell Malignancy?

There are 4 clinical trials targeting B-cell Malignancy tracked by BioSniper.

Deep-dive into B-cell Malignancy

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

B-cell Malignancy — Drugs in Development & Clinical Trials | BioSniper